Skip to main content
. 2022 Dec 23;12(12):e063903. doi: 10.1136/bmjopen-2022-063903

Table 1.

Data collection and time points for each CID

Baseline or 0’ (fasting) 10’ 15’ 20’ 30’ 45’ 60’ 120’ 180’ Next day
Primary endpoint Subjective appetite (VAS for hunger, desire to eat, fullness, prospective food consumption) X X X X X X X X
Behavioural endpoints Food preference and reward (LFPQ) X X
Food cravings (CoEQ) X
Energy intake (24-hour dietary recall) X
Expected satiety X (1 bite)
Sensory-specific satiety X (1 bite) X
Other appetite ratings (eg, thirst, nausea, bloating, appetite for something sweet/savoury) X X X X X X X
Metabolic endpoints Glucose and insulin X X X X X X
Pancreatic polypeptide (PP)* X X X X
GLP-1 and ghrelin X X X
Lipaemia (triglycerides, total cholesterol, HDL-cholesterol and LDL-cholesterol) X X X X
Health endpoints Liver function (ALT, AST, GGT, FL index, TyG index) X X
HbA1c CID1 and 6
24-hour GI side effects (self-report) X

*Time points for PP are earlier for yoghurt study.

ALT, alanine transaminase; AST, aspartate transaminase; CID, clinical investigation day; CoEQ, Control of Eating Questionnaire; FL index, fatty liver index; GGT, gamma-glutamyltransferase; GI, gastrointestinal; GLP-1, glucagon-like peptide 1; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LFPQ, Leeds Food Preference Questionnaire; TyG index, triglycerides and glucose index; VAS, Visual Analogue Scale.